Clinical Interest for Patients
I am interested in advancing precision medicine for lung cancer which includes identifying new gene targets. It also includes understanding mechanisms of resistance to targeted therapies. When I am not seeing patients in the clinic I run a laboratory that is developing new models for cancer research and studying mechanisms of drug resistance to targeted therapies.
Providing the most up-to-date care for lung care using precision medicine and immunotherapy approaches when appropriate.
- Medical Oncology ( 2007 )
Conditions & Treatments
Skiing, hiking, camping, and travel.
MD, University of Pennsylvania School of Medicine (2001)
AB, Princeton University (NJ) (1993)
PhD, University of Pennsylvania (2001)
University of Chicago Program (2002)
University of Chicago Program (2004)
University of Chicago Program (2007)
American Association for Cancer Research (AACR), Member
American Society of Clinical Oncology (ASCO), Member
International Association for the Study of Lung Cancer (IASLC), Member
Southwestern Oncology Group (SWOG), Member
University of Colorado Cancer Center, Associate Member
The role of EGFR as a mechanism of therapeutic resistance in gene fusion positive lung cancer. (2016)
SPORE In Lung Cancer (2017)
Research Interests for Patients
My research interests are primary focused on oncogene-driven cancer (ALK, ROS1, RET, NTRK1/2/3, MET, EGFR) and drug-resistance to targeted therapies. My laboratory derives new cancer models by making human cell lines and interrogating these models to understand how to better treat cancers with combination targeted therapies.